- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations
- Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA)
- On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025
- 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner
- Strong financial position with approximately $1.0 billion in cash and investments providing runway into mid-2027
- Conference call scheduled for May 7, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
2025 Financial Guidance
Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund its operations into mid-2027.
Conference Call
Vir Biotechnology will host a conference call to discuss the first quarter results at 1:30 p.m. PT / 4:30 p.m. ET today. A live webcast will be available on https://investors.vir.bio and will be archived for 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.